Dr. Clay Siegall is an industry leader in genetic research. He has vast experience and knowledge after being involved with genetics for over twenty years. His company, Seattle Genetics, was formed in 1998. Before being a co-founder there, Siegall worked at Bristol-Myers Squibb Pharmaceutical Research Institute for six years in the 1990s and the National Cancer Institute, National Institutes of Health from 1988 to 1991. Currently a Board member of the Alder Bio Pharmaceuticals and Mirna Therapeutics, Siegall is involved with a number of other professional organizations and groups. He has written over 70 industry publications and holds the rights to fifteen different patents.
Long before co-founding Seattle Genetics, Siegall received a Bachelor of Science degree in Zoology from the University of Maryland and later a doctorate in Genetics from George Washington University. His current work with developing products for antibody-based cancer solutions has been innovative and his work garnered attention on a national level when the work was given accelerated approval in 2011 by the U.S. Food and Drug Administration.
At Seattle Genetics, Siegall has a strong team developing the latest in antibody-based therapies. As a collaborator with biotechnology and pharmaceutical companies, he will be well-positioned to be confident in his work as he works on raising capital in both the private sector and in public. Siegall has already secured over $675 million since the company went public in 2001. His successes will continue as Seattle Genetics continues to develop innovative antibody-based cancer therapies. The future of genetics is bright with Dr. Siegall and Seattle Genetics.